Development of 99mtc labelled lipiodol: biodistribution following injection into the hepatic artery of the healthy pig

Nuclear Medicine Communications

Volumn 25, Issue 3, 2004, Pages 291-297

  Garin, Etienne ^a   Noiret, Nicolas ^a   Malbert, Charles Henri ^a   Lepareur, Nicolas ^a   Roucoux, Alain ^a   Dazord, Léontine ^a   Caulet Maugendre, Sylvie ^a   Turlin, Bruno ^a   Moisan, Annick ^a   Lecloirec, Joseph ^a   Herry, Jean Yves ^a   Boucher, Eveline ^a   Raoul, Jean Lue ^a   Bourguet, Patrick ^a  

^a Nucléaire Centre Eugène Marquis   (United States)

Author keywords

Animal; Hepatocellular carcinoma; Lipiodol; Liver; Rhenium; Technetium

Indexed keywords

IODINATED POPPYSEED OIL; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; CHELATING AGENT; TECHNETIUM 99M;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CHEMISTRY; DRUG DETOXIFICATION; DRUG EFFECT; EVALUATION; FEASIBILITY STUDY; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; ISOTOPE LABELING; METABOLISM; METHODOLOGY; SWINE; SYNTHESIS; TISSUE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AUTORADIOGRAPHY; DOSIMETRY; DRUG DISTRIBUTION; DRUG LABELING; DRUG PURITY; DRUG SYNTHESIS; INJECTION; NONHUMAN; RADIATION PROTECTION; RADIOCHEMISTRY;

ANIMALS; FEASIBILITY STUDIES; HEPATIC ARTERY; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; ISOTOPE LABELING; METABOLIC DETOXICATION, DRUG; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; SWINE; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 5144222493     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200403000-00013     Document Type: Article

References (36)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
2. Trinchet JC, Beaugrand M. Augmentation de l’incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 1999; 23:1286-1288.
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1974-1994. Lancet 1997; 350:1142-1143.
4. Deuffic S, Poynard T. Trends in primary liver cancer. Lancet 1998; 351:214-215.
5. Okuda K. Hepatocellular carcinoma. J Hepathol 2000; 32(suppl 1):225-237.
6. Suarez Y, Sala M, Llovet JM, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 1999; LXII:410-414.
7. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76:4-11.
8. Garin E, Bourguet P. Radiolipiodol of liver tumors. In: Ell PJ, Gambhir S, (editors). Nuclear Medicine in Clinical Diagnosis and Treatment. 3rd edition. Edinburgh: Elsevier Science; (in press).
9. 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
10. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
11. Lau WY, Leung TWT, Ho SKW, Chan M, Machin D, Lau J, et al. Adjuvant intra-arterial iodine-131-labelled Lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353:797-801.
12. 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003; 24:671-678.
13. Wang SJ, Lin WY, Chen MN, Shen LH, Tsai ZT, Tina G. Preparation and biodistribution of yttrium-90 lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 1995; 22:233-236.
14. Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT, Ting G. Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatome. J Nucl Med 1996; 37:332-335.
15. 188Re for hepatic tumor therapy. Appl Radiat Isot 1996; 47:267-271.
16. Wang SJ, Lin WY, Chen MN, Hsieh BT, Shen LH, Tsai ZT, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996; 23:13-17.
17. 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001; 28:197-204.
18. 188Re labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002; 23:237-242.
19. Sundram FX, Jeong JM, Zanzonico P, Bernal P, Chau T, Onkhuudai P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002; 1:5-11.
20. Mévellec F, Tisato F, Refosco F, Roucoux A, Noiret N, Patin H, et al. Synthesis and characterization of the ‘sulfur-rich’ bis(perthiobenzoato)(dithiobenzoato)technetium(III) heterocomplex. Inorg Chem 2002; 41:589-601.
21. Perrin DD, Armarego WLF. Purification of organic chemicals. In: Purification of Laboratory Chemicals. 3rd edition. New York: Pergamon; 1988, pp. 65-309.
22. Noll B, Kniess T, Friebi M, Spies H, Johannsen B Rhenium V glucorate, suitable precursor for the preparation of rhenium V complexes. Isotopenpraxis 1996; 32:21.
23. Pasqualini R, Bellande E, Comazi V, Duatti A. Improved synthesis of Tc-99m-nitridodithiocarbamate myocardial imaging agents. J Nucl Med 1992; 33:989-990.
24. 111In-DTPA-octreotide. Eur J Nucl Med 2001; 28:1743-1750.
25. 188Re(V)DMSA distribution in patients with prostate cancer mestastatic to bone. Eur J Nucl Med 2000; 27:1405-1409.
26. Iznaga-escobar N, Torres LA, Morales A, Ramos M, Alvarez I, Pérez N, et al. Technetium-99m-labelled anti-EGF-receptor antibody in patients with tumor of epithelial origin, I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med 1998; 39:15-23.
27. 2: their in vitro localization and chemical behaviour. Nucl Med Biol 1997; 24:701-705.
28. 2)8CS2. The cellular and subcellular distribution in human blood cells, and chemical behaviour. Synthesis of the analogous rhenium-188 radiopharmaceutical. Nucl Med Biol 1999; 26:225-231.
29. Raoul JL, Duvauferrier R, Bourguet P, Bretagne JF, Coornaert S, Darnault P, et al. L’angiographie lipiodolée au cours des carcinomes hépatocellulaires. Apport du Lipiodol marqué à l’iode 131. J Radiol 1986; 67:797-801.
30. Raoul JL, Bourguet P, Bretagne JF, Duvauferrier R, Coornaert S, Darnault P, et al. Hepatic artery injection of I-131-labeled Lipiodol. Part 1. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168:541-545.
31. Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution and in vivo kinetics of iodine 131 Lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29:1066-1077.
32. Eary JF, Durack L, Williams D, Vanderheyden JL. Considerations for imaging Re-188 and Re-186 isotopes. Clin Nucl Med 1990; 15:911-916.
33. Hambye AS, Dobbeleir AA, Vervaet AM, Knapp Jr FF. Image quality with rhenium-188 and technetium-99m: comparative planar and SPECT evaluation in a phantom study and implications for dosimetry. World J Nucl Med 2002; 1:12-20.
34. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative doses of iodine-131. Thyroid 1994; 4:49-54.
35. Leger FA, Izembart M, Dagousset F, Barriault L, Baillet G, Chevalier A, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
36. Kan Z, Ivancev K, Hägerstrand I, Chuang VP, Lunderquist A. In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol 1989; 30:419-425.